CORTCorcept Therapeutics Inc.

Corcept Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that modulate cortisol activity to address serious endocrine, oncologic, metabolic, and neurologic disorders. Its commercial portfolio is centered on Korlym, an oral therapy used for adults with endogenous Cushing’s syndrome and related hypercortisolism. The company also advances a pipeline of selective cortisol modulators across multiple therapeutic areas, including relacorilant for Cushing’s syndrome and certain cancers, Lifyorli for oncology, and other investigational programs in metabolic disease and amyotrophic lateral sclerosis. Corcept Therapeutics serves the specialized rare-disease and specialty-pharmaceutical markets, where its products and research are aimed at conditions with limited treatment options. The company is headquartered in Redwood City, California.